Company profile
Grace Therapeutics, Inc.
NASDAQ: GRCE · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
48DFH 66DQ 23GM —SS 45
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, Altman-Z · ↓ revenue growth (YoY), Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$7.8M
Employees
5
as of 2026-08-20
Market cap
$35.8M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02022
Net income-$7.8M-$7.8M2026
Operating income-$11.1M-$11.1M2026
Total assets$66.7M$66.7M2026
Liabilities$2.8M$2.8M2026
Equity$63.9M$63.9M2026
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Grace Therapeutics, Inc.’s revenue?
Grace Therapeutics, Inc. booked $0 in FY2022 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Instil Bio, Inc.36DTenax Therapeutics, Inc.49DNoveris Health Sciences Inc.——NanoViricides, Inc.35DLite Strategy, Inc.49DHigh Sierra Technologies, Inc.——Neighbors
Mercer →Key facts
CEOPrashant Kohli
SectorHealthcare
IndustryBiotechnology
HeadquartersPrinceton, NJ
ExchangeNASDAQ: GRCE
Employees5
IPO date2012-02-07
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.